NLS Pharmaceutics AG (NASDAQ:NLSPW) — Market Cap & Net Worth
Market Cap & Net Worth: NLS Pharmaceutics AG (NLSPW)
NLS Pharmaceutics AG (NASDAQ:NLSPW) has a market capitalization of $177.10 ($177.10) as of September 18, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #32002 globally and #6427 in its home market, demonstrating a 37.69% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying NLS Pharmaceutics AG's stock price $0.02 by its total outstanding shares 9894 (9.89K). Also see NLS Pharmaceutics AG total assets for a full breakdown of the balance sheet.
NLS Pharmaceutics AG Market Cap History: 2021 to 2025
NLS Pharmaceutics AG's market capitalization history from 2021 to 2025. Data shows change from $4.95K to $177.10 (-54.14% CAGR). Also see NLSPW cash flow conversion for how efficiently the company converts equity into cash flow.
NLS Pharmaceutics AG Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how NLS Pharmaceutics AG's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Check today's stock price for NLS Pharmaceutics AG for real-time trading data and today's change.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of NLSPW by Market Capitalization
Companies near NLS Pharmaceutics AG in the global market cap rankings as of September 18, 2026. Review NLS Pharmaceutics AG tangible net worth ratio to assess the quality of the company's equity after excluding intangible assets.
Key companies related to NLS Pharmaceutics AG by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #187 globally with a market cap of $130.09 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #353 globally with a market cap of $78.34 Billion USD.
- CSL Ltd (AU:CSL): Ranked #457 globally with a market cap of $59.87 Billion USD ( AU$84.62 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #505 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #187 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.09 Billion | $513.26 |
| #353 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $78.34 Billion | $774.61 |
| #457 | CSL Ltd | AU:CSL | $59.87 Billion | AU$174.41 |
| #505 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $145.62 |
NLS Pharmaceutics AG Historical Marketcap From 2021 to 2025
Between 2021 and today, NLS Pharmaceutics AG's market cap moved from $4.95K to $ 177.10, with a yearly change of -54.14%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2025 | $177.10 | +37.69% |
| 2024 | $128.62 | -76.79% |
| 2023 | $554.06 | -80.69% |
| 2022 | $2.87K | -42.00% |
| 2021 | $4.95K | -- |
End of Day Market Cap According to Different Sources
On Sep 17th, 2026 the market cap of NLS Pharmaceutics AG was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $177.10 USD |
| MoneyControl | $177.10 USD |
| MarketWatch | $177.10 USD |
| marketcap.company | $177.10 USD |
| Reuters | $177.10 USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About NLS Pharmaceutics AG
NLS Pharmaceutics AG, a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies for patients with rare and complex central nervous system disorders. The company is focusing on the development of treatments for narcolepsy, idiopathic hypersomnia, and other rare sleep disorders, as well as neurodevelopmental disorders, such as attention deficit hyperactivity … Read more